• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, September 22, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Scientists developing model to predict if chemotherapy will work for breast cancer

Bioengineer by Bioengineer
December 8, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CHAPEL HILL– University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators are working to predict, before treatment, whether an aggressive type of breast cancer will respond to chemotherapy.

In a study presented at the 2016 San Antonio Breast Cancer Symposium, researchers report they developed a model that can predict which triple negative breast cancer patients will respond to chemotherapy. Katherine Hoadley, PhD, a UNC Lineberger member and assistant professor in the UNC School of Medicine Department of Genetics, said the model was moderately successful at predicting response, but more work is needed to improve its accuracy.

"Our goal was to identify a gene expression signature pattern in cancer cells that might be able to help us predict who's going to respond to chemotherapy prior to actually giving the treatment," said Hoadley, the study's first author.

Triple negative breast cancer is a particularly aggressive breast cancer type that has no targeted treatments. Patients with this disease do have higher response rates to chemotherapy, however, compared with some other subtypes. While targeted treatments are designed to attack specific molecular features that help drive cancer, chemotherapy more widely attacks all rapidly dividing cells.

Hoadley said knowing in advance which triple negative breast cancer patients will respond to chemotherapy could help physicians determine the best course of treatment.

To develop the prediction model, researchers analyzed the expression of genes from breast cancer samples drawn from 389 patients before treatment, and they also drew upon data on how those patients responded to treatment. They split the sample data into training and test sets. Gene expression signatures were analyzed in the training set to identify the signatures that best associated with a complete response to treatment. They then used the signatures they uncovered to determine the ability to predict response in the remaining samples.

They found the model could predict which samples had a complete pathologic response for 68 percent of patients who actually did achieve pathologic complete response to the treatment. And for patients who did have residual disease after chemotherapy, the test successfully indicated they did not have pathologic complete response for 64 percent of those cases.

Hoadley said the researchers will continue to work on the model to improve its accuracy. She said they plan to include other features of cancer cells in their model, such as molecular indicators of how the immune system is responding to the cancer, genetic mutations and the number of copies of each gene.

"If we can validate our model in future data sets, our work could help us identify patients who are likely to respond to existing, or even less, chemotherapy and those who could benefit from more chemotherapy or novel approaches," she said.

###

In addition to Hoadley, other authors include: Terry Hyslop, PhD; Chris Fan, MS, Donald A. Berry, PhD; Olwen Hahn, MD; Sara M. Tolaney, MD, MPH; Charles M. Perou, PhD; and Lisa Carey, MD.

This project is supported by and the National Cancer Institute and the Breast Cancer Research Foundation. Susan G. Komen supported the collection of biopsies at UNC. Hoadley is supported by a grant from Susan G. Komen.

Media Contact

Laura Oleniacz
[email protected]
919-445-4219

http://cancer.med.unc.edu/

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Vizient logo

UC San Diego Health named national leader in delivering high-quality patient care

September 22, 2023
Connectome of Health

Editorial addresses clinician burnout with unifying systems medicine model

September 22, 2023

Louisiana Cancer Research Center Associate Director of Administration Sven Davisson named Treasurer of Association of Independent Research Institutes

September 22, 2023

Pioneering health tracker for stroke survivors will use the body to transmit data

September 22, 2023
Please login to join discussion

POPULAR NEWS

  • blank

    Microbe Computers

    58 shares
    Share 23 Tweet 15
  • University of South Florida scientist: Barnacles may help reveal location of lost Malaysia Airlines flight MH370

    46 shares
    Share 18 Tweet 12
  • Lithuanian invention at the forefront of solar technology breakthrough

    41 shares
    Share 16 Tweet 10
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

UC San Diego Health named national leader in delivering high-quality patient care

Editorial addresses clinician burnout with unifying systems medicine model

Louisiana Cancer Research Center Associate Director of Administration Sven Davisson named Treasurer of Association of Independent Research Institutes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In